CI-919

Known as: CI 919, CI919 
 
National Institutes of Health

Topic mentions per year

Topic mentions per year

1983-1985
01219831985

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
1986
1986
Antibacterial activity of enoxacin was evaluated against more than 3,700 clinical isolates using the agar-dilution method and an… (More)
Is this relevant?
1986
1986
The in-vitro activities of four quinolone carboxylic acids against 423 clinical isolates of Gram-negative rods and staphylococci… (More)
Is this relevant?
1986
1986
The in-vitro antimicrobial activity of five new quinolones, enoxacin (CI-919, AT-2266), ciprofloxacin (Bay o 9867), amifloxacin… (More)
Is this relevant?
1985
1985
Enoxacin (CI-919; AT-2266), a new naphthyridine derivative was found to induce morphologic changes at very low concentrations in… (More)
Is this relevant?
1984
1984
The in-vitro activity of enoxacin (CI-919), a new synthetic quinoline derivative was compared with that of three other quinolines… (More)
Is this relevant?
1984
1984
The in vitro activity of enoxacin (CI 919, AT 2266), a new oral quinolone carboxylic acid compound, was compared with those of… (More)
  • table 1
Is this relevant?
1984
1984
Enoxacin (CI-919) was evaluated for activity against 120 multiply resistant clinical isolates of the family Enterobacteriaceae… (More)
Is this relevant?
1983
1983
We tested CI-919 (AT-2266), a nalidixic acid analog, against 555 gram-positive and gram-negative bacteria, using microbroth or… (More)
Is this relevant?
1983
1983
The in vitro susceptibilities of 50 strains of Salmonella spp., 80 strains of Shigella spp., and 50 enterotoxigenic Escherichia… (More)
Is this relevant?